According to The Insight Partners' research, the Europe Point of Care Diagnostics Market was valued at US$ 8,939.5 Million in 2024 and is expected to reach US$ 21,407.3 Million by 2031, registering a CAGR of 13.4% from 2025 to 2031.
Rising product launches and advancements by market players in emerging economies and increasing prevalence of infectious diseases are among the critical factors attributed to driving the Europe point of care diagnostics market growth.
For business expansion, market players are focusing on emerging nations, such as India, China, and Brazil, due to the large population suffering from HIV and other infectious diseases. Advancements in nanotechnology and genomics are increasing the demand for diagnostics in the healthcare sector, encouraging the introduction of a greater number of point-of-care test systems and facilitating the shift toward personalized medicine. There are new opportunities in infectious disease testing, molecular oncology, and pharmacogenomics in emerging countries. The development of nanomaterials and nanotechnology has promoted the progress of POCT platforms, which are widely used in colorimetric, optical, electrochemical, magnetic, and catalytic approaches. The point of care testing platforms are used to detect nucleic acids, proteins, pesticides, viruses, bio-markers in disease diagnosis, and even heavy-metal species. Thus, rising product launches and advancements in emerging countries are anticipated to provide ample growth opportunities for the point-of-care diagnostics market during the forecast period.
On the contrary, the product recalls hamper the growth of the Europe point of care diagnostics market.
Europe Point of Care Diagnostics Market Segmentation Analysis:
- By Product, the Europe Point of Care Diagnostics Market is segmented into Glucose Monitoring, Infectious Disease Testing, Cardio metabolic Testing, Pregnancy and Fertility Testing, Coagulation Testing, Tumor or Cancer Marker Testing, Cholesterol Testing, Urinalysis Testing, Hematology Testing, Thyroid Testing, and Others. The Glucose Monitoring segment is projected to expand at 16.0% CAGR during 2025 - 2031.
- By Glucose Monitoring, the Europe Point of Care Diagnostics Market is segmented into Blood Glucose Meter, Lancet, and Strips. The Strips segment is projected to expand at 15.5% CAGR during 2025 - 2031.
- By Infectious Disease Testing, the Europe Point of Care Diagnostics Market is segmented into HIV Testing, Influenza Testing, Sexually Transmitted Diseases Testing, Hepatitis C Virus Testing, Tropical Diseases Testing, Respiratory Infection Testing, Hospital Acquired Infections, and Others. The Respiratory Infection Testing segment is projected to expand at 17.2% CAGR during 2025 - 2031.
- By Cardio Metabolic Testing, the Europe Point of Care Diagnostics Market is segmented into Cardiac Troponin (cTn) Test, Myoglobin Test, and Others. The Cardiac Troponin (cTn) Test segment is projected to expand at 13.5% CAGR during 2025 - 2031.
- By Purchase Mode, the Europe Point of Care Diagnostics Market is segmented into OTC and Prescription. The Prescription segment is projected to expand at 12.9% CAGR during 2025 - 2031
- By Sample, The Europe Point of Care Diagnostics Market is segmented into Blood, Urine, and Others. The Blood segment is projected to expand at 13.8% CAGR during 2025 - 2031.
- By End User, the Europe Point of Care Diagnostics Market is segmented into Healthcare Facilities, Homecare, and Others. The Healthcare Facilities segment is projected to expand at 13.4% CAGR during 2025 - 2031.
- By Healthcare Facilities, the Europe Point of Care Diagnostics Market is segmented into Hospitals and Clinics, Diagnostic Centers, and Others. The Diagnostic Centers segment is projected to expand at 13.7% CAGR during 2025 - 2031.
By country, the Europe Point of Care Diagnostics Market is categorized into the United Kingdom, Germany, France, Italy, Spain, and the Rest of Europe. Germany is projected to expand at 14.1% CAGR during 2025 - 2031.
Key players operating in the Point of Care Diagnostics Market are Siemens AG, Abbott Laboratories, F. Hoffmann-La Roche Ltd, bioMerieux SA, Bio-Rad Laboratories Inc, QIAGEN NV, Nova Biomedical Corporation, Polymer Technology Systems, Inc. (PTS), and Danaher Corp, among others.
- In February 2022, Siemens Healthineers and the United Nations Children's Fund UNICEF announced a partnership to help strengthen fragile health systems in sub-Saharan Africa by improving access to diagnostics and linkage to treatment. Through a 5 million EUR grant, Siemens Healthineers will support UNICEF's work helping to prevent maternal, newborn and child deaths and promote the health and development of all children.
Contact Us
Phone: +1-646-491-9876
Email Id: sales@theinsightpartners.com